Advancing Immunotherapy Frontiers: Dispatch Bio Doses First Patient in Phase I Trial of DISP-10 for Advanced Gastrointestinal Cancers
Executive Overview In a significant milestone for modern oncology and the evolution of cell-based immunotherapies, clinical-stage biopharmaceutical company Dispatch Bio has officially dosed the first human participant in a pivotal…